Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-22
    E.g., 2018-02-22

Articles

13818 items
8:50 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Neuropathy Mouse studies suggest inhibiting HDAC3 could help treat peripheral neuropathies. In a mouse model of sciatic nerve injury, tool compound HDAC3 inhibitors increased the number of myelin-producing Schwann cells at the injury site and...
8:50 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Mouse studies suggest inhibiting IL-4 alone or in combination with IL-13 could help treat gastric cancer. In a mouse model of gastric cancer, systemic double-knockout of IL-4 and IL-13 decreased the number of...
8:50 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected donors,...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif ligand-binding...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest CXCL12-secreting Lactobacillus reuteri could help treat wounds. In a human skin biopsy-based model of wound healing, L. reuteri engineered to secrete CXCL12 increased the length of epidermal sleeves...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Frog studies suggest DDX21 mRNA could help treat Treacher Collins syndrome, a craniofacial disorder caused by mutations in the TCOF1 or Pol I genes. In a Xenopus embryo model of the syndrome, injection of...
4:51 PM, Feb 08, 2018  |  BC Innovations | Product R&D

Debugging the microbiome

BiomX Ltd. is moving phage therapies beyond infectious disease and into chronic conditions driven by the microbiome. The Israeli biotech has pieced together a suite of tools that can identify bad actors within microbial communities...
4:41 PM, Feb 08, 2018  |  BC Innovations | Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
3:07 PM, Feb 08, 2018  |  BC Innovations | Finance

External rethink

As the industry seeks to develop new ways to access external innovation, companies are re-evaluating the value of public-private partnerships, and increasingly turning to other companies for research partnerships in lieu of broad deals with...
3:02 PM, Feb 08, 2018  |  BC Innovations | Translation in Brief

Proteomic pathfinding

Biognosys is using a method developed by ETHZ researchers for the unbiased detection of molecular targets based on protein-metabolite interactions to study inter- and intra-patient variances in the proteome. The protein services CRO will also offer...

Pages